13 Key Takeaways on Quality Agreements, Tech Transfer, and Risk Management in Cell and Gene Therapy

As cell and gene therapy programs move from early development toward the clinic – and increasingly toward accelerated and breakthrough commercialization pathways – the margin for error continues to shrink. Manufacturing readiness, quality systems, and risk management are no longer downstream concerns; they are strategic decisions that are critical to aggressive timelines and stand up to regulatory scrutiny.

In a recent webinar, our Chief Quality Officer Luciana Mansolelli and CMC Advisor Audrey Chang explored how quality agreements, tech transfer practices, and risk-based decision-making can either enable or constrain progress in advanced therapies. The discussion focused on real-world lessons from sponsors and CDMOs navigating compressed timelines, evolving regulatory expectations, and complex cross-organizational collaborations.

The following 13 key takeaways capture the most important insights from the webinar- highlighting why early quality integration, strong data discipline, and thoughtful CDMO partnerships are critical to building programs that shape speed to clinic, regulatory confidence, and ultimately patient access.

In cell and gene therapy, quality decisions made early in development directly influence speed to clinic, scalability, regulatory success, and ultimately patient access. Treating quality as a downstream checkpoint creates rework, delays, and avoidable regulatory friction.

Lesson learned: Programs that embed quality thinking early retain flexibility later – especially when timelines compress unexpectedly.

QA delivers the greatest value when embedded in process design, development discussions, and early risk assessments- not when introduced at approval or validation stages. “Shifting left” enables knowledge transfer rather than documentation handoffs during tech transfer.

Lesson learned: QA involvement early in development is an investment that pays off in later development by reducing surprises, revalidation, and late-stage regulatory friction.

Effective quality agreements do much more than define responsibilities. They establish decision rights, escalation pathways, data transparency expectations, and lifecycle governance. They also serve as alignment tools across organizations with differing QA maturity.

Lesson learned: Strong quality agreements accelerate execution by reducing ambiguity and enabling risk-based collaboration- not by adding bureaucracy.

Audience discussion reinforced that flexibility must never dilute foundational GMP principles. Patient safety, product identity, data integrity, and traceability are non-negotiable and must be clearly defined at the outset of any sponsor-CDMO relationship.

Lesson learned: Early clarity on non-negotiables builds trust and prevents downstream conflict while enabling appropriate flexibility elsewhere.

In advanced therapies, uncontrolled speed- not compliance- is the true risk. Regulatory flexibility exists, but only when decisions are grounded in scientific justification, documented risk acceptance, and clear plans to increase control over time.

Lesson learned: Quality does not slow development; poor early decisions do.

Product release timelines are frequently constrained by testing, not manufacturing. Adoption of alternative and rapid testing methods can meaningfully reduce time to release without compromising safety.

Lesson learned: Release acceleration strategies should be incorporated into the manufacturing strategy.

Digitization enables scale, traceability, and learning- but only when data quality is incorporated from the start. AI and machine learning amplify existing systems; they cannot compensate for fragmented data or weak fundamentals.

Lesson learned: Digital maturity is driven by data discipline, not technology adoption alone.

Comparability challenges during tech transfer are often the result of weak early data practices. Robust potency assays, retained samples, and deep understanding of critical process parameters enable comparability pathways without full revalidation or additional clinical burden.

Lesson learned: You cannot retrofit data integrity- early discipline becomes future flexibility.

Process knowledge gaps in QA cannot be solved with shortcuts. Structured training, cross-functional rotations between quality and operations, and continuous exposure to evolving technologies and regulations are required to build resilient quality organizations.

Lesson learned: Organizations that invest in QA capability development reduce long-term compliance risk and increase operational agility.

Beyond technical execution, CDMOs contribute value through exposure to diverse modalities, processes, and regulatory scenarios. This experience enables application of best practices and avoidance of known pitfalls- even when specifics cannot be shared.

Lesson learned: The most effective CDMO partnerships leverage experience, not just capacity.

Many CGT programs transition rapidly from early to later phases due to breakthrough or accelerated designations. Programs that defer quality maturity early often struggle when timelines suddenly compress.

Lesson learned: Phase-appropriate quality should be designed with acceleration in mind – not used as a reason to delay discipline.

Consistent quality systems, transparent data practices, and early engagement with regulators build confidence that can shorten review cycles and support post-approval flexibility.

Lesson learned: Regulatory trust is earned incrementally – and pays dividends when speed matters most.

Every quality decision – good or bad – directly affects patients waiting for therapy. Disciplined, science-driven quality systems enable speed with confidence and reduce the risk of delays that matter most at the patient level.

Lesson learned: In advanced therapies, quality is not a cost center – it is a determinant of patient impact.

Across all modalities and development stages, one theme from the webinar was unmistakable: quality is not an administrative requirement or a late-stage checkpoint- it is a foundational enabler of speed, scalability, and patient impact. Programs that embed quality early, invest in data integrity, and approach risk with scientific rigor are better positioned to navigate accelerated pathways, smooth tech transfers, and evolving regulatory expectations.

Equally clear was the role of experience. Whether through well-constructed quality agreements, phase-appropriate system design, or proactive testing strategies, organizations that leverage seasoned quality and manufacturing partners reduce uncertainty and avoid costly rework when timelines compress.

If you’d like to explore how these principles apply to your own cell or gene therapy program- or want to speak with subject matter experts in quality assurance, quality control or early-stage development – our team is here to help. We also invite you to learn more about our cell therapy services, viral vector development and manufacturing capabilities and the biosafety testing services we offer across multiple modalities including mAbs, viral vaccines and cell and gene therapies.